



Prof. Dr. med. Lukas Flatz

**Principal Investigator and Senior Consultant
attending physician**

Dermatologie | Venerologie | Allergologie · Interdisciplinary Medical Services

Contact

Prof. Dr. med. Lukas Flatz
Switzerland

Lukas.Flatz@kssg.ch

Additional Information

Co-founder of ArenaVax and Hookipa Biotech

Units

Dermatologie | Venerologie | Allergologie

Position

Principal Investigator and Senior Consultant

Profile Function

attending physician

Research Area

melanoma, immunotherapy, cancer vaccine, basal cell carcinoma, recombinant viral vectors,

Affiliations

University of Zurich (Medical Faculty)

Patents

1. Replication-defective Arenavirus Vectors.

International Publication Date: 9 July 2009

International Publication Number: WO 2009/083210 A1

2. Prime-boost vaccine strategies incorporating lymphocytic choriomeningitis virus vaccines to protect against lentiviral infection.

U.S. Patent Application No. 61/489,205, filed on May 23, 2011

Publications (87)

Núñez N, Berner F, Friebel E, Unger S, Wyss N, Gomez J, Purde M, Niederer R, Porsch M, Lichtensteiger C, Kramer R, Erdmann M, Schmitt C, Heinzerling L, Abdou M, Karbach J, Schadendorf D, Zimmer L, Ugurel S, Klümper N, Hölzel M, Power L, Kreutmair S, Capone M, Madonna G, Cevhertas L, Heider A, Amaral T, Hasan Ali O, Bomze D, Dimitriou F, Diem S, Ascierto P, Dummer R, Jäger E, Driessen C, Levesque M, van de Veen W, Joerger M, Früh M, Becher B, Flatz L. Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. *Med (N Y)* 2023

Sinnberg T, Lichtensteiger C, Ali O, Pop O, Risch L, Brugger S, Velic A, Bomze D, Kohler P, Vernazza P, Albrich W, Kahlert C, Abdou M, Wyss N, Hofmeister K, Niessner H, Zinner C, Gilardi M, Tzankov A, Röcken M, Dulovic A, Shambat S, Ruetalo N, Buehler P, Scheier T, Jochum W, Kern L, Henz S, Schneider T, Kuster G, Lampart M, Siegemund M, Bingisser R, Schindler M, Schneiderhan-Marra N, Kalbacher H, McCoy K, Spengler W, Brutsche M, Macek B, Twerenbold R, Penninger J, Matter M, Flatz L, Jochum A. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. *Am J Respir Crit Care Med* 2023; 207:38-49.

Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörgen M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neeffes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. *Sci Immunol* 2022; 7:eabn9644.

Sinnberg T, Lichtensteiger C, Hill-Mündel K, Leischner C, Niessner H, Busch C, Renner O, Wyss N, Flatz L, Lauer U, Hoelzle L, Nohr D, Burkard M, Marongiu L, Venturelli S. Vitamin C Deficiency in Blood Samples of COVID-19 Patients. *Antioxidants (Basel)* 2022; 11

Yurchenko A, Pop O, Ighilahriz M, Padioleau I, Rajabi F, Sharpe H, Poulalhon N, Dreno B, Khammari A, Delord M, Alberti A, Soufir N, Battistella M, Mourah S, Bouquet F, Savina A, Besse A, Mendez-Lopez M, Grange F, Monestier S, Mortier L, Meyer N, Dutriaux C, Robert C, Saiag P, Herms F, Lambert J, de Sauvage F, Dumaz N, Flatz L, Basset-Seguín N, Nikolaev S. Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma. *Clin Cancer Res* 2022; 28:1422-1432.

Klümper N, Saal J, Berner F, Lichtensteiger C, Wyss N, Heine A, Bauernfeind F, Ellinger J, Brossart P, Diem S, Schmid S, Jörgen M, Frueh M, Ritter M, Hölzel M, Flatz L, Bald T. C reactive protein flare predicts response to checkpoint inhibitor treatment in non-small cell lung cancer. *J Immunother Cancer* 2022; 10

Bösch M, Baty F, Albrich W, Flatz L, Rodriguez R, Rothschild S, Jörgen M, Früh M, Brutsche M. Local tumor microbial signatures and response to checkpoint blockade in non-small cell lung cancer. *Oncoimmunology* 2021; 10:1988403.

Purde M, Niederer R, Wagner N, Diem S, Berner F, Hasan Ali O, Hillmann D, Bergamin I, Jörgen M, Risch L, Niederhauser C, Lenz T, Früh M, Risch L, Semela D, Flatz L. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients. *J Cancer Res Clin Oncol* 2021; 148:647-656.

Serna-Higuaita L, Eigentler T, Garbe C, Thomas I, Seeber O, Flatz L, Leiter U, Forschner A, Amaral T, Martus P. Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. *Cancers (Basel)* 2021; 13

Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludwig B, Driessen C, Jörgen M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neeffes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. *Oncoimmunology* 2021; 10:2006893.

Keim U, Gandini S, Amaral T, Katalinic A, Hollecsek B, Flatz L, Leiter U, Whiteman D, Garbe C. Cutaneous melanoma attributable to UVR exposure in Denmark and Germany. *Eur J Cancer* 2021; 159:98-104.

Weber J, Flatz L, Sommacal A, Varde M. Large Hemorrhagic Extrascleral Ciliary Body Melanoma Recurrence Treated With Transarterial Embolization and Coiling Followed by Exenteration. *Ophthalmic Plast Reconstr Surg.* 2021; 37:e184-e187.

Weber J, Flatz L, Sommacal A, Varde M. Large Hemorrhagic Extrascleral Ciliary Body Melanoma Recurrence Treated With Transarterial Embolization and Coiling Followed by Exenteration. *Ophthalmic Plast Reconstr Surg.* 2021; 37:e184-e187.

Ring S, Spiegl M, Besse A, Bonilla W, Stemeseder F, Schmidt S, Orlinger K, Krebs P, Ludewig B, Wenger R, Hartmann F, Cupovic J, Onder L, Lütge M, Perez Shibayama C, Gil Cruz C, Scandella E, De Martin A, Mörbe U, Flatz L. Viral vector-mediated reprogramming of the fibroblastic tumor stroma sustains curative melanoma treatment. *Nat Commun* 2021; 12:4734.

Cupovic J, Klenerman P, Engeler D, Krebs P, Scandella E, Oxenius A, Flatz L, Provine N, De Martin A, Cheng H, Lütge M, Colston J, Onder L, Ring S, Ludewig B. Adenovirus vector vaccination reprograms pulmonary fibroblastic niches to support protective inflating memory CD8 T cells. *Nat Immunol* 2021; 22:1042-1051.

Garbe C, Leiter U, Flatz L, Martus P, Hollecsek B, Katalinic A, Amaral T, Gandini S, Keim U, Whiteman D. Epidemiology of cutaneous melanoma and keratinocyte cancer in white populations 1943-2036. *Eur J Cancer* 2021; 152:18-25.

Bilich T, Flatz L, Held S, Brossart P, Märklin M, Wagner P, Erne E, Klein R, Rammensee H, Salih H, Berner F, Wacker M, Roerden M, Maringer Y, Nelde A, Heitmann J, Dubbelaar M, Peter A, Hörber S, Bauer J, Rieth J, Walz J. Preexisting and Post-COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer. *Cancer Discov* 2021; 11:1982-1995.

Baldauf M, Kapauer M, Jörger M, Flatz L, Rodriguez R, Frank S, Felbecker A, Hundsberger T. Pembrolizumab-Associated CD8 Vasculitic Mononeuritis Multiplex in a Patient With Mesothelioma. *Neurol Neuroimmunol Neuroinflamm* 2021; 8

Królik M, Csepregi L, Hartmann F, Engetschwiler C, Flatz L. Recombinant lymphocytic choriomeningitis virus-based vaccine vector protects type I interferon receptor deficient mice from viral challenge. *Vaccine* 2021; 39:1257-1264.

Hasan Ali O, Penninger J, Bergthaler A, Popa A, Gómez-Mejía A, Schüpbach R, Bühler P, Vernazza P, Kahlert C, Kohler P, Albrich W, Kern L, Thiel S, Weber M, Paprotny M, Brugger S, Risch L, Bomze D, Flatz L. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. *Clin Infect Dis* 2021; 73:e2869-e2874.

Wagner N, Schraag A, Klumpp B, Hoetzenecker W, Berking C, Richtig E, Ziemer M, Mangana J, Terheyden P, Loquai C, Nguyen V, Gebhardt C, Meier F, Diem S, Cozzio A, Flatz L, Röcken M, Garbe C, Gassenmaier M, Weide B, Leiter U, Lenders M, Kühn K, Reinhardt L, André F, Dudda M, Ring N, Ebel C, Stäger R, Zellweger C, Lang R, Paar M, Gussek P, Richtig G, Stürmer S, Kimeswenger S, Oellinger A, Forschner A, Eigentler T. Pretreatment metastatic growth rate determines clinical outcome of advanced melanoma patients treated with anti-PD-1 antibodies: a multicenter cohort study. *J Immunother Cancer* 2021; 9

Bickel A, Diem S, Flatz L, Stinn B, Siano M. First-line treatment of NRAS-mutated metastatic melanoma with a MEK inhibitor. *J Cancer Res Ther* 2021; 17:276-278.

Bochem J, Meier F, Terheyden P, Königsrainer A, Garbe C, Flatz L, Pawelec G, Eigentler T, Löffler M, Weide B, Niessner H, Sinnberg T, Zelba H, Spreuer J, Amaral T, Gaissler A, Pop O, Thiel K, Yurttas C, Soffel D, Forchhammer S, Wistuba-Hamprecht K. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy. *J Immunother Cancer* 2021; 9

Winter J, Eigentler T, Garbe C, Röcken M, Cozzio A, Flatz L, Purde M, Weide B, Leiter U, Forschner A, Gassenmaier M, Lenders M, Wagner N. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors. *Cancer Immunol Immunother* 2020; 70:1089-1099.

Bald T, Scolyer R, Long G, Wilmott J, Hughes B, Ahern E, Taheri T, Kristiansen G, Geyer M, Hölzel M, Seo E, Batstone M, Landsberg J, Smyth M, Martinet L, Johnston R, Möller A, Nicholson S, Veillette A, Dougall W, Flatz L, Pop O, Dietrich D, Nakamura K, Casey M, Koufariotis L, Li R, Li K, Meza Guzman L, Lima L, Das I, Krumeich S, Stannard K, Corvino D, Sundarajan A, Aguilera A, Salim N, Jorge M, Quine B, Effern M, Jacquelin S, Madore J, Pearson S, Raghavendra A, Lepletier A, Vari F, Kelly G, Ham S, Braun M. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8 T Cells. *Immunity* 2020; 53:805-823.e15.

Ring S, Królik M, Hartmann F, Schmidt E, Ali O, Ludewig B, Kochanek S, Flatz L. Heterologous Prime Boost Vaccination Induces Protective Melanoma-Specific CD8 T Cell Responses. *Mol Ther Oncolytics* 2020; 19:179-187.

Bomze D, Asher N, Hasan A, Flatz L, Azoulay D, Markel G, Meirson T. Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. *JAMA Netw Open* 2020; 3:e2017675.

Baron R, Bodmer T, Imperiali M, Heer S, Renz H, Flatz L, Kohler P, Vernazza P, Kahlert C, Paprotny M, Ferrara F, Egli K, Risch L, Weber M, Thiel S, Grossmann K, Wohlwend N, Lung T, Hillmann D, Ritzler M, Bigler S, Risch M. Frequency of serological non-responders and false-negative RT-PCR results in SARS-CoV-2 testing: a population-based study. *Clin Chem Lab Med* 2020; 58:2131-2140.

Fröhlich A, Ring S, Golletz C, Pietsch T, Strieth S, Brossart P, Gielen G, Kristiansen G, Bootz F, Landsberg J, Flatz L, Hoffmann F, Sirokay J, Fietz S, Vogt T, Dietrich J, Zarbl R, Florin M, Kuster P, Saavedra G, Valladolid S, Dietrich D. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma. *EBioMedicine* 2020; 59:102962.

Hasan Ali O, Hundsberger T, Diem S, Müller S, Pop O, Markert E, Müller J, Moulin A, Ring S, Ackermann C, Berner F, Flatz L. Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. *Cancer Immunol Immunother* 2020; 70:563-568.

Bomze D, Meirson T, Hasan A, Goldman A, Flatz L, Habet-Wilner Z. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. *Ocul Immunol Inflamm* 2020:1-7.

Effern M, Gebhardt T, Bald T, Tüting T, Flatz L, Smyth M, Landsberg J, Aymans P, Daoud M, van den Boorn-Konijnenberg D, Hinze D, Bawden E, Yong M, Boll H, Liebing J, Braun M, Glodde N, Hölzel M. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. *Immunity* 2020; 53:564-580.e9.

Hoffmann F, Landsberg J, Kristiansen G, Flatz L, Pietsch T, Dietrich J, Ring S, Gielen G, Strieth S, Kuster P, Saavedra G, Brossart P, Holderried T, Posch C, Fröhlich A, Sirokay J, Niebel D, Zarbl R, Dietrich D. Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma. *Clin Epigenetics* 2020; 12:94.

Hasan Ali O, Navarini A, Kim A, French L, Dermitzakis E, Christiano A, Hohl D, Bickers D, Nikolaev S, Jochum W, Fritzsche F, Yurchenko A, Pavlova O, Sartori A, Bomze D, Higgins R, Ring S, Hartmann F, Bühler D, Flatz L. Genomic profiling of late-onset basal cell carcinomas from two brothers with nevoid basal cell carcinoma syndrome. *J Eur Acad Dermatol Venereol* 2020

van de Veen W, Huntjens D, Wallimann A, Fonseca Guevara R, Spits H, Desislava I, Chang Y, Fassnacht C, Guenova E, Flatz L, Akdis C, van Splunter M, Stanić B, Herrmann M, Globinska A, Jansen K, Straumann A, Kubo T, Verschoor D, Wirz O, Castro-Giner F, Tan G, Rückert B, Ochsner U, Akdis M. A novel proangiogenic B cell subset is increased in cancer and chronic inflammation. *Sci Adv* 2020; 6:eaaz3559.

Huber M, Chiticariu E, Bachmann D, Flatz L, Hohl D. Palmoplantar Keratoderma with Leukokeratosis Anogenitalis Caused by KDSR Mutations. *J Invest Dermatol* 2020; 140:1662-1665.e1.

Gil Cruz C, Jahns R, Wyss M, Mooser C, Lambrecht B, Maeder M, Rickli H, Flatz L, Eriksson U, Geuking M, McCoy K, Boivin-Jahns V, Slack E, Arnoldini M, Perez Shibayama C, De Martin A, Ronchi F, Van der Borgh K, Niederer R, Onder L, Lütge M, Novkovic M, Nindl V, Ramos G, Ludewig B. Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. *Science* 2019; 366:881-886.

Berner F, Bomze D, Flatz L. Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply. *JAMA Oncol* 2019

Hasan Ali O, Sadik C, Zillikens D, Schmidt E, Jochum W, Mani B, Cozzio A, Braun A, Emtenani S, Hammers C, Abdou M, Diem S, Fässler M, Berner F, Ring S, Bomze D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. *J Am Acad Dermatol* 2019; 82:854-861.

Bomze D, Hasan Ali O, Bate A, Flatz L. Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. *JAMA Oncol* 2019

Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. *JAMA Oncol* 2019; 5:1043-1047.

Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.

Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolik M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Perez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.

Trefny M, Savic S, Jermann P, Alborelli I, Schaub S, Stenner F, Früh M, Trajanoski Z, Flatz L, Mertz K, Zippelius A, Geier F, Thommen D, Rothschild S, Uhlenbrock F, Rieder D, Kasenda B, Stanczak M, Berner F, Kashyap A, Kaiser M, Herzig P, Poehtrager S, Läubli H. A Variant of a Killer Cell Immunoglobulin-like Receptor Is Associated with Resistance to PD-1 Blockade in Lung Cancer. *Clin Cancer Res* 2019; 25:3026-3034.

Isak V, Beerli T, Cozzio A, Flatz L. A Rare Case of Localized Argyria on the Face. *Case Rep Dermatol* 2019; 11:23-27.

Hartwig T, Schlapbach C, Conrad C, Flatz L, Dummer R, Navarini A, Cheng P, Yawalkar N, Schreiner B, Zwicky P, Becher B. Regulatory T Cells Restrain Pathogenic T Helper Cells during Skin Inflammation. *Cell Rep* 2018; 25:3564–3572.e4.

Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. *Eur J Cancer* 2018; 107:8–14.

Diem S, Früh M, Güsewell S, Schmid S, Ackermann C, Roux G, Berner F, Niederer R, Siano M, Ali O, Fässler M, Flatz L. Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. *Cancer Manag Res* 2018; 10:5537–5544.

Schmid S, Jochum W, Klingbiel D, Desbiolles L, Leschka S, Flatz L, Krapf M, Li Q, Diem S, Früh M. Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). *Cancer Immunol Immunother* 2018

Fischer S, Ali O, Jochum W, Kluckert J, Flatz L, Siano M. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. *Oncol Res Treat* 2018; 41:391–394.

Diem S, Hasan Ali O, Ackermann C, Bomze D, Koelzer V, Jochum W, Speiser D, Mertz K, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. *Cancer Immunol Immunother* 2017; 67:39–45.

Remy M, Merkler D, Kaufmann B, Hanisch U, Bestmann L, Rieger T, Doras C, Fallet B, Kreutzfeldt M, Xu L, Regen T, Flatz L, Sahin M, Pinschewer D. Interferon- γ -Driven iNOS: A Molecular Pathway to Terminal Shock in Arenavirus Hemorrhagic Fever. *Cell Host Microbe* 2017; 22:354–365.e5.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. *Lung Cancer* 2017; 111:176–181.

Kalkavan H, Rathbun J, Cannon P, Scheu S, Bauer J, Chauhan J, Häussinger D, Willimsky G, Löhning M, Schadendorf D, Brandau S, Schuler M, Lang P, Drexler I, von Laer D, Wollmann G, Sharma P, Kasper S, Helfrich I, Pandyra A, Gassa A, Virchow I, Flatz L, Brandenburg T, Namineni S, Heikenwalder M, Höchst B, Knolle P, Lang K. Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. *Nat Commun* 2017; 8:14447.

Hasan Ali O, Diem S, Aschwanden J, Markert E, Tasman A, Müller J, Flatz L. GLUT1-positive recurrent basal cell carcinoma of basosquamous subtype detected by positron emission tomography. *JAAD Case Rep* 2016; 2:415–417.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L, Speiser D, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. *Oncoimmunology* 2016; 5:e1231292.

Bickel A, Koneth I,ENZLER-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. *BMC cancer* 2016; 16:656.

Diem S, Goldinger S, Urner-Bloch U, Siano M, Dummer R, Speiser D, Maillard S, Rüesch R, Keller F, Flatz L. Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?. *J Immunother* 2016; 39:379–382.

Ring S, Flatz L. Generation of Lymphocytic Choriomeningitis Virus Based Vaccine Vectors. *Methods Mol Biol* 2016; 1404:351-64.

Demaria O, Speiser D, Modlin R, Martinon F, Petrova T, Hwu P, Michielin O, Gaide O, Flatz L, Di Domizio J, Gesteremann N, Coso S, De Gassart A, Gilliet M. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity. *Proc Natl Acad Sci USA* 2015; 112:15408-13.

Sommerstein R, Siegrist C, Lambert P, Bowden T, Coutard B, Rabah N, Meda P, Rigo D, Ter Meulen J, Igonet S, Bergthaler A, Sahin M, Fischer N, Magistrelli G, Malinge P, Remy M, Flatz L, Pinschewer D. Arenavirus Glycan Shield Promotes Neutralizing Antibody Evasion and Protracted Infection. *PLoS Pathog* 2015; 11:e1005276.

Bhattacharya A, Arnold I, Flatz L, Xu H, Lang P, Aderem A, Takaoka A, Superti-Furga G, Colinge J, Ludewig B, Löhning M, Baazim H, Khamina K, Panse I, Hegazy A, Deigendesch N, Kosack L, Cupovic J, Kandasamy R, Hildebrandt A, Merkler D, Kühl A, Vilagos B, Schliehe C, Bergthaler A. Superoxide Dismutase 1 Protects Hepatocytes from Type I Interferon-Driven Oxidative Damage. *Immunity* 2015; 43:974-86.

Johnson S, Bergthaler A, Graw F, Flatz L, Bonilla W, Siegrist C, Lambert P, Regoes R, Pinschewer D. Protective efficacy of individual CD8+ T cell specificities in chronic viral infection. *J Immunol* 2015; 194:1755-62.

Roychoudhuri R, Sékaly R, Restifo N, Cameron M, Gilliet M, Nabel G, Gattinoni L, Goulet J, Hegazy A, Fourati S, Nichols C, Klebanoff C, Ji Y, Pan L, Honda M, Lefebvre F, Flatz L. Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation. *Vaccine* 2014; 33:914-23.

Sommerstein R, Ramos da Palma J, Olschläger S, Bergthaler A, Barba L, Lee B, Pasquato A, Flatz L. Evolution of Recombinant Lymphocytic Choriomeningitis Virus/Lassa Virus In Vivo Highlights the Importance of the GPC Cytosolic Tail in Viral Fitness. *J Virol* 2014; 88:8340-8348.

Speiser D, Flatz L. Cancer immunotherapy drives implementation science in oncology. *Hum Vaccin Immunother* 2014; 10:3107-10.

Clayton H, Flatz L, Vollenweider-Roten S, Schoepfer A, Gilliet M, Conrad C. Anti-TNF therapy in the treatment of psoriasis in a patient with acute-on-chronic pancreatitis. *Dermatology (Basel)* 2013; 227:193-6.

Olschläger S, Flatz L. Vaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trials. *PLoS Pathog* 2013; 9:e1003212.

Flatz L, Conrad C. Role of T-cell-mediated inflammation in psoriasis: pathogenesis and targeted therapy. *Psoriasis: Targets & Therapy* 2013

Zürcher S, Schaller A, Gorgievski-Hrisoho M, Garzoni C, Mohacsi P, Barbani M, Mühlemann K, Lüthi A, Mooser C, Flatz L. Sensitive and rapid detection of ganciclovir resistance by PCR based MALDI-TOF analysis. *J Clin Virol* 2012; 54:359-63.

Flatz L, Donaldson M, Schmidt S, Gall J, Pinschewer D, Letvin N, Rao S, Mascola J, Roederer M, Shen L, Asmal M, Todd J, Cheng C, Wang L, Foulds K, Ko S, Kong W, Roychoudhuri R, Shi W, Bao S, Nabel G. Gene-based vaccination with a mismatched envelope protects against simian immunodeficiency virus infection in nonhuman primates. *J Virol* 2012; 86:7760-70.

Kerber R, Rieger T, Busch C, Flatz L, Pinschewer D, Kümmerer B, Günther S. Cross-species analysis of the replication complex of Old World arenaviruses reveals two nucleoprotein sites involved in L protein function. *J Virol* 2011; 85:12518–28.

Flatz L, Sékaly R, Haddad E, Roederer M, Lin M, Kettaf N, Goulet J, Filali-Mouhim A, Honda M, Roychoudhuri R, Nabel G. Single-cell gene-expression profiling reveals qualitatively distinct CD8 T cells elicited by different gene-based vaccines. *Proc Natl Acad Sci USA* 2011; 108:5724–9.

Bergthaler A, Flatz L, Hegazy A, Johnson S, Horvath E, Löhning M, Pinschewer D. Viral replicative capacity is the primary determinant of lymphocytic choriomeningitis virus persistence and immunosuppression. *Proc Natl Acad Sci USA* 2010; 107:21641–6.

Pinschewer D, Flatz L, Steinborn R, Horvath E, Fernandez M, Lutz H, Suter M, Bergthaler A. Innate and adaptive immune control of genetically engineered live-attenuated arenavirus vaccine prototypes. *Int Immunol* 2010; 22:749–56.

Flatz L, Günther S, Hanisch U, Brück W, Kreuzfeldt M, Verschoor A, Bestmann L, Schedensack M, Regen T, Bergthaler A, Merkler D, Rieger T, Pinschewer D. T cell-dependence of Lassa fever pathogenesis. *PLoS Pathog* 2010; 6:e1000836.

Flatz L, Radbruch A, Levy F, Lambert P, Siegrist C, Restifo N, Löhning M, Ochsenbein A, Nabel G, Broek M, Kochanek S, Hegazy A, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Pinschewer D. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. *Nat Med* 2010; 16:339–45.

Hegazy A, Radbruch A, Pinschewer D, Flatz L, Bergthaler A, Fröhlich A, Panse I, Helmstetter C, Peine M, Löhning M. Interferons direct Th2 cell reprogramming to generate a stable GATA-3(+)-bet(+) cell subset with combined Th2 and Th1 cell functions. *Immunity* 2010; 32:116–28.

Bergthaler A, Siegrist C, Odermatt B, Verbeek J, Senn B, Fitsche A, Fernandez M, Horvath E, Sommerstein R, Merkler D, Eschli B, Fink K, Holdener M, Hegazy A, Verschoor A, Flatz L, Pinschewer D. Impaired antibody response causes persistence of prototypic T cell-contained virus. *PLoS Biol* 2009; 7:e1000080.

Lang P, Ohashi P, Ludwig B, Honda K, Bergthaler A, Flatz L, Pellegrini M, Recher M, Navarini A, Verschoor A, Cervantes-Barragan L, Lang K. Hematopoietic cell-derived interferon controls viral replication and virus-induced disease. *Blood* 2009; 113:1045–52.

Heikenwalder M, Nedospasov S, Holländer G, Macpherson A, Rülcke T, Flatz L, Priller J, Schmidt H, Tumanov A, Rossi S, Junt T, Lang K, Zeller N, Prinz M, Aguzzi A. Overexpression of lymphotoxin in T cells induces fulminant thymic involution. *Am J Pathol* 2008; 172:1555–70.

Navarini A, Hengartner H, Odermatt B, Landmann R, Bille J, Flatz L, Bergthaler A, Meury S, Georgiev P, Lang K, Recher M, Zinkernagel R. Increased susceptibility to bacterial superinfection as a consequence of innate antiviral responses. *Proc Natl Acad Sci USA* 2006; 103:15535–9.

Flatz L, Bergthaler A, de la Torre J, Pinschewer D. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. *Proc Natl Acad Sci USA* 2006; 103:4663–8.

Cottagnoud P, Pfister M, Acosta F, Cottagnoud M, Flatz L, Kühn F, Müller H, Stucki A. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. *Antimicrob Agents Chemother* 2004; 48:3928–33.

Flatz L, Cottagnoud M, Kühn F, Entenza J, Stucki A, Cottagnoud P. Ceftriaxone acts synergistically with levofloxacin in experimental meningitis and reduces levofloxacin-induced resistance in penicillin-resistant pneumococci. *J Antimicrob Chemother* 2004; 53:305-10.

Cottagnoud P, Cottagnoud M, Acosta F, Flatz L, Kühn F, Stucki A, Entenza J. Meropenem prevents levofloxacin-induced resistance in penicillin-resistant pneumococci and acts synergistically with levofloxacin in experimental meningitis. *Eur J Clin Microbiol Infect Dis* 2003; 22:656-62.

Kühn F, Cottagnoud M, Acosta F, Flatz L, Entenza J, Cottagnoud P. Cefotaxime acts synergistically with levofloxacin in experimental meningitis due to penicillin-resistant pneumococci and prevents selection of levofloxacin-resistant mutants in vitro. *Antimicrob Agents Chemother* 2003; 47:2487-91.

Projects (3)

T002-080413-9 Version 2, 27 May 2020 Page 1 of 68 CLINICAL STUDY PROTOCOL PH-L19IL2TNFNMSC-04/19 A phase II study of intratumoral administration of L19IL2/L19TNF in non-melanoma skin cancer patients with presence of injectable lesions

Clinical Studies - Aug 2, 2020 - Jan 25, 2030

Ongoing

Immunmonitoring of patients before, during and after immunotherapy to predict anti-tumor response in melanoma and non-small cell lung cancer (IMIT)

Clinical Studies - Jul 15, 2016 - Oct 15, 2019

Automatically Closed

Vaccine and immunotherapy induced CD8+ T cell responses against auto-, neo- and foreign antigens

Fundamental Research - Jan 1, 2016 - Dec 31, 2019

Automatically Closed

Kantonsspital St.Gallen
Rorschacher Strasse 95
CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch